BioSpace News Archive

OmniSpirant Limited and EVerZom are delighted to announce the launch of INSPIRE, a €12.8 million lung cancer project funded by Horizon Europe.

Forward Pharma A/S, announced that the Enlarged Board of Appeal of the European Patent Office has denied Forward’s petition for review of the decision of the Technical Board of Appeal of the EPO that confirmed the revocation of the EP2801355 patent by the EPO Opposition Division in the opposition proceeding.

ADMA Biologics, Inc., an end-to-end commercial biopharmaceutical company dedicated to manufacturing, marketing and developing specialty plasma-derived biologics, announced that it intends to offer shares of its common stock for sale in an underwritten public offering.

Hologic, Inc. (Nasdaq: HOLX) and its subsidiary, Biotheranostics, Inc., today announced new study data showing that the Breast Cancer Index test identified which premenopausal patients with early-stage, hormone-receptor positive (HR+) breast cancer benefited from the addition of ovarian function suppression (OFS) to primary adjuvant endocrine therapy.

Cybin Inc. (NEO:CYBN) (NYSE American: CYBN) (Cybin or the Company), a biopharmaceutical company focused on progressing Psychedelics to Therapeutics®, today announced that the Company presented two posters on its deuterated psilocybin analog, CYB003, at the American College of Neuropsychopharmacology (“ACNP”) annual meeting taking place December 4-7, 2022, in Phoenix, Arizona.

Baudax Bio, Inc. announced the closing of its previously announced public offering of an aggregate of 1,042,787 shares of its common stock, Series A-3 warrants to purchase up to 1,042,787 shares of common stock and Series A-4 warrants to purchase 1,042,787 shares of common stock, at a combined public offering price of $4.795 per share and accompanying warrants.

Albireo Pharma, Inc., a rare liver disease company developing novel bile acid modulators to treat pediatric and adult liver diseases, announced the grant of inducement restricted stock units to acquire 13,700 shares of Albireo’s common stock.

Vapotherm, Inc. announced that it was notified on November 30, 2022 by the New York Stock Exchange, Inc. that the Company is not in compliance with the NYSE’s continued listing standard set forth in Section 802.01C of the NYSE’s Listed Company Manual because the average closing price of the Company’s common stock was less than $1.00 per share over a consecutive 30 trading-day period.

Parnell Pharmaceuticals Holdings Ltd commenced its previously announced backstopped rights offering to raise gross proceeds of approximately US$4.0 million.

Syndax Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company developing an innovative pipeline of cancer therapies, announced the pricing of an underwritten public offering of 6,818,182 shares of its common stock.